Oxidative stress markers and mitochondrial antioxidant enzyme expression are increased in aggressive Hodgkin lymphomas

Histopathology

Volumn 65, Issue 3, 2014, Pages 319-327

  Bur, Hamid ^a   Haapasaari, Kirsi Maria ^a   Turpeenniemi Hujanen, Taina ^a   Kuittinen, Outi ^a   Auvinen, Päivi ^b   Marin, Katja ^b   Koivunen, Petri ^a   Sormunen, Raija ^a   Soini, Ylermi ^c   Karihtala, Peeter ^a  

^a OULU UNIVERSITY HOSPITAL   (Finland)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

^c UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

8 OHdG; MnSOD; Peroxiredoxin; Prognosis; Reactive oxygen species

Indexed keywords

3 NITROTYROSINE; 8 HYDROXYDEOXYGUANOSINE; ANTIOXIDANT; BIOLOGICAL MARKER; BLEOMYCIN; DACARBAZINE; DOXORUBICIN; MANGANESE SUPEROXIDE DISMUTASE; PEROXIREDOXIN 2; PEROXIREDOXIN 3; PEROXIREDOXIN 5; PEROXIREDOXIN 6; REACTIVE OXYGEN METABOLITE; VINBLASTINE; 3-NITROTYROSINE; 8-OXO-7-HYDRODEOXYGUANOSINE; DEOXYGUANOSINE; PEROXIREDOXIN; SUPEROXIDE DISMUTASE; TUMOR MARKER; TYROSINE;

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER RESISTANCE; CELL INFILTRATION; CONTROLLED STUDY; CYTOPLASM; CYTOSOL; DISEASE ASSOCIATION; FEMALE; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; IMMUNOELECTRON MICROSCOPY; IMMUNOHISTOCHEMISTRY; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; MAJOR CLINICAL STUDY; MALE; MITOCHONDRION; NEUTROPHIL; OXIDATIVE STRESS; PLASMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RECURRENCE FREE SURVIVAL; TRANSMISSION ELECTRON MICROSCOPY; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; METABOLISM; PATHOLOGY; PROGNOSIS; REED STERNBERG CELL;

ADULT; ANTIOXIDANTS; DEOXYGUANOSINE; FEMALE; HODGKIN DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICROSCOPY, IMMUNOELECTRON; MITOCHONDRIA; OXIDATIVE STRESS; PEROXIREDOXINS; PROGNOSIS; REED-STERNBERG CELLS; SUPEROXIDE DISMUTASE; TUMOR MARKERS, BIOLOGICAL; TYROSINE;

EID: 84927580967     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12389     Document Type: Article

References (36)

1. Bonadonna G, Bonfante V, Viviani S et al. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results. J. Clin. Oncol. 2004; 22; 2835-2841.
2. Kuruvilla J, Keating A, Crump M. How I treat relapsed and refractory Hodgkin lymphoma. Blood 2011; 117; 4208-4217.
3. Finkel T. Oxidant signals and oxidative stress. Curr. Opin. Cell Biol. 2003; 15; 247-254.
4. Karihtala P, Puistola U. Hypoxia and oxidative stress in the pathogenesis of gynecological cancers and in therapeutical options. Curr. Cancer Ther. Rev. 2011; 7; 37-55.
5. Evans MD, Dizdaroglu M, Cooke MS. Oxidative DNA damage and disease: induction, repair and significance. Mutat. Res. 2004; 567; 1-61.
6. Kasai H. Analysis of a form of oxidative DNA damage, 8-hydroxy-2′-deoxyguanosine, as a marker of cellular oxidative stress during carcinogenesis. Mutat. Res. 1997; 387; 147-163.
7. Radi R, Rodriguez M, Castro L et al. Inhibition of mitochondrial electron transport by peroxynitrite. Arch. Biochem. Biophys. 1994; 308; 89-95.
8. Jakobisiak M, Lasek W, Golab J. Natural mechanisms protecting against cancer. Immunol. Lett. 2003; 90; 103-122.
9. Rabilloud T, Heller M, Gasnier F et al. Proteomics analysis of cellular response to oxidative stress. Evidence for in vivo overoxidation of peroxiredoxins at their active site. J. Biol. Chem. 2002; 277; 19396-19401.
10. Kang SW, Baines IC, Rhee SG. Characterization of a mammalian peroxiredoxin that contains one conserved cysteine. J. Biol. Chem. 1998; 273; 6303-6311.
11. Okado-Matsumoto A, Matsumoto A, Fujii J et al. Peroxiredoxin IV is a secretable protein with heparin-binding properties under reduced conditions. J. Biol. Chem. 2000; 127; 493-501.
12. Declercq JP, Evrard C, Clippe A et al. Crystal structure of human peroxiredoxin 5, a novel type of mammalian peroxiredoxin at 1.5 A resolution. J. Mol. Biol. 2001; 311; 751-759.
13. Kinnula VL, Lehtonen S, Sormunen R et al. Overexpression of peroxiredoxins I, II, III, V and VI in malignant mesothelioma. J. Pathol. 2002; 196; 316-323.
14. Valko M, Izakovic M, Mazur M et al. Role of oxygen radicals in DNA damage and cancer incidence. Mol. Cell. Biol. 2004; 266; 37-56.
15. Goel A, Spitz DR, Weiner GJ et al. Manipulation of cellular redox parameters for improving therapeutic responses in B-cell lymphoma and multiple myeloma. J. Cell. Biochem. 2012; 113; 419-425.
16. Pasanen AK, Kuitunen H, Haapasaari KM et al. Expression and prognostic evaluation of oxidative stress markers in an immunohistochemical study of B-cell derived lymphomas. Leuk. Lymphoma 2012; 53; 624-631.
17. Peroja P, Pasanen AK, Haapasaari KM et al. Oxidative stress and redox state-regulating enzymes have prognostic relevance in diffuse large B-cell lymphoma. Exp. Hematol. Oncol. 2012; 1; 2. (http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3506993/)
18. Slot JW, Geuze HJ. A novel method to make gold probes for multiple labeling cytochemistry. Eur. J. Cell Biol. 1985; 38; 87-93.
19. Bertolotti M, Sitia R, Rubartelli A. On the redox control of B lymphocyte differentiation and function. Antioxid. Redox Signal. 2012; 16; 1139-1149.
20. Solaini G, Sgarbi G, Baracca A. Oxidative phosphorylation in cancer cells. Biochim. Biophys. Acta 2011; 1807; 534-542.
21. Morabito F, Cristani M, Saija A et al. Lipid peroxidation and protein oxidation in patients affected by Hodgkin's lymphoma. Mediators Inflamm. 2004; 13; 381-383.
22. Hirano T. Repair system of 7, 8-dihydro-8-oxoguanine as a defense line against carcinogenesis. J. Radiat. Res. 2008; 49; 329-340.
23. Karihtala P, Kauppila S, Soini Y et al. Oxidative stress and counteracting mechanisms in hormone receptor positive, triple-negative and basal-like breast carcinomas. BMC Cancer 2011; 11; 262. (http://www.biomedcentral.com/1471-2407/11/262)
24. Karihtala P, Kauppila S, Puistola U et al. Divergent behaviour of oxidative stress markers 8-hydroxydeoxyguanosine (8-OHdG) and 4-hydroxy-2-nonenal (HNE) in breast carcinogenesis. Histopathology 2011; 58; 854-862.
25. Sova H, Jukkola-Vuorinen A, Puistola U et al. 8-Hydroxydeoxyguanosine: a new potential independent prognostic factor in breast cancer. Br. J. Cancer 2010; 102; 1018-1023.
26. Ock CY, Hong KS, Choi KS et al. A novel approach for stress-induced gastritis based on paradoxical anti-oxidative and anti-inflammatory action of exogenous 8-hydroxydeoxyguanosine. Biochem. Pharmacol. 2011; 81; 111-122.
27. Liu M, Gong X, Alluri RK et al. Characterization of RNA damage under oxidative stress in Escherichia coli. Biol. Chem. 2012; 393; 123-132.
28. Chung YM, Yoo YD, Park JK et al. Increased expression of peroxiredoxin II confers resistance to cisplatin. Anticancer Res. 2001; 21; 1129-1133.
29. Wang J, Zu J, Xu G et al. Inhibition of focal adhesion kinase induces apoptosis in human osteosarcoma SAOS-2 cells. Tumour Biol. 2013; 35; 1551-1556.
30. Kim JH, Bogner PN, Ramnath N et al. Elevated peroxiredoxin 1, but not NF-E2-related factor 2, is an independent prognostic factor for disease recurrence and reduced survival in stage I non-small cell lung cancer. Clin. Cancer Res. 2007; 13; 3875-3882.
31. Dorr RT. Bleomycin pharmacology: mechanism of action and resistance, and clinical pharmacokinetics. Semin. Oncol. 1992; 19; 3-8.
32. Fang J, Nakamura H, Iyer AK. Tumor-targeted induction of oxystress for cancer therapy. J. Drug Target. 2007; 15; 475-486.
33. Devita VT, Hellman S, Rosenberg SA. Cancer: Principles and Practice of Oncology. 7th ed. Philadelphia: Lippincott Williams & Wilkins, 2004.
34. Knoops B, Goemaere J, Van der Eecken V et al. Peroxiredoxin 5: structure, mechanism, and function of the mammalian atypical 2-Cys peroxiredoxin. Antioxid. Redox Signal. 2011; 15; 817-829.
35. Cox AG, Winterbourn CC, Hampton MB. Mitochondrial peroxiredoxin involvement in antioxidant defence and redox signalling. Biochem. J. 2009; 425; 313-325.
36. The Human Protein Atlas. Available at: http://www.proteinatlas.org/ENSG00000126432 (accessed 11 October 2013).